Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current issues in adeno-associated viral vector production.

O-W Merten1, C Gény-Fiamma, A M Douar

  • 1Genethon, 1 bis, rue de l'Internationale, Evry, France.

Gene Therapy
|October 19, 2005
PubMed
Summary

Adeno-associated virus (AAV) vectors show promise for gene therapy, excelling in differentiated tissues. Advances in AAV production and purification are crucial for widespread clinical application.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Large-scale production means for the manufacturing of lentiviral vectors.

Current gene therapy·2010
Same author

Attention with virus contaminated cell lines.

Cytotechnology·2008
Same author

Evaluation of a Serum-free Medium for the Production of rAAV-2 using HeLa Derived Producer Cells.

Cytotechnology·2008
Same author

Introduction to animal cell culture technology-past, present and future.

Cytotechnology·2008
Same author

Virus contaminations of cell cultures - A biotechnological view.

Cytotechnology·2008
Same author

Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice.

Gene therapy·2006

Area of Science:

  • Biotechnology
  • Gene Therapy
  • Viral Vector Technology

Background:

  • Adeno-associated virus (AAV) is a leading candidate for human gene therapy.
  • Preclinical studies demonstrate AAV's safety and efficacy in postmitotic tissues like muscle, CNS, and liver.
  • Clinical trials confirm AAV's potential but highlight production challenges.

Purpose of the Study:

  • To review the current state of recombinant AAV (rAAV) production methods.
  • To analyze the advantages and disadvantages of different rAAV production techniques.
  • To identify key challenges for advancing AAV vector manufacturing for clinical use.

Main Methods:

  • Review of existing literature on AAV production methodologies.
  • Comparative analysis of various recombinant AAV (rAAV) production systems.
  • Discussion of purification strategies and quality control measures.

Main Results:

  • AAV vectors exhibit strong performance in specific differentiated tissues.
  • Current production and purification methods require significant technological advancement for scalability and quality.
  • Existing methods have distinct applications, advantages, and limitations.

Conclusions:

  • Further innovation in AAV manufacturing is essential for broader clinical translation.
  • Addressing production and purification challenges will facilitate AAV's wider adoption in gene therapy.
  • Optimizing AAV vector batch quality is critical for human applications.

Related Experiment Videos